Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing small molecule product candidates that target lysine-specific demethylase-1, an enzyme that plays a role in the production of blood cells in the bone marrow. Co. is focused on improving the quality of life of patients with cancer and bone marrow diseases in addition to prolonging their lives. Co.'s primary product candidate is bomedemstat for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. The three most common MPNs are myelofibrosis, essential thrombocythemia, and polycythemia vera. We show 7 historical shares outstanding datapoints in our IMGO shares outstanding history coverage, used to compute IMGO market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing IMGO market cap history over the course of time is important for investors
interested in comparing IMGO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of IMGO versus a peer is one thing; comparing
IMGO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like IMGO can fluctuate over the course of history.
With this page we aim to empower investors researching IMGO by allowing them to research the IMGO market cap history. |
Free IMGO Email Alerts:
Video: The Importance of Market Cap
